REG - Trellus Health PLC - Notice of Results

Trellus HealthAnnouncement

16/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240416:nRSP7112Ka&default-theme=true

RNS Number : 7112K  Trellus Health PLC  16 April 2024

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Notice of Results

Investor Presentation

 

LONDON, U.K. AND NEW YORK, U.S. (16 April 2024). Trellus Health plc (AIM:
TRLS), a health services company delivering innovative, scientifically
validated programs and technologies that facilitate the comprehensive
management of chronic conditions, improving health outcomes whilst managing
costs of care, announces that it expects to report its final results for the
year ended 31 December 2023 on Tuesday 23 April 2024.

 

Investor Presentation

 

Dr. Marla Dubinsky, CEO and Co-Founder, and Joy Bessenger, Chief Financial
Officer, will provide a live presentation relating to the final results via
Investor Meet Company on Wednesday 24 April 2024 at 4.00pm (BST).

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Trellus Health plc via:

https://www.investormeetcompany.com/trellus-health-plc/register-investor
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.investormeetcompany.com_trellus-2Dhealth-2Dplc_register-2Dinvestor&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=WovxkIrimZbJDsUY12yOjDzcN9uTu1TmGAhgw0TiZCY&m=u2s_HwtDZpJMmMQPlRU1EP0Zrlad12xhdkQuB9yIHwg&s=JyITwz-8wuTjjFZP5xalEdxGH7mXtK1Ak16pYVSQsAI&e=)

 

Investors who already follow Trellus Health plc on the Investor Meet Company
platform will automatically be invited.

 

For further information please contact:

 

 Trellus Health plc                                                           https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, CEO and Co-Founder                                       Via Walbrook PR
 Dr. Daniel Mahony, Chairman

 Singer Capital Markets (Nominated Adviser and Broker)                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR                                  Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                                              (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen / Phillip Marriage  Mob: +44 (0)7980 541 893 / (0)7502 558 258/ (0)7867 984 082

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (AIM: TRLS) is a health services company providing value-based
innovative solutions and services for chronic condition management that
prioritises improved outcomes and member experiences while managing costs of
care.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced experience that meets
each individual's unique needs and empowers them to master their physical and
emotional health. Trellus Elevate's™ clinically proven solutions result in
relieving disease burden, building self-management skills and promoting
positive health behaviours that improve outcomes and enables thriving in the
face of a chronic condition.

 

The Company's proven whole person approach recognises the interconnectedness
of various aspects of a person's life and aims to address the whole spectrum
of factors that influence behaviour, to promote comprehensive well-being and
human flourishing in a way that aligns with value-based care. Trellus Health's
approach enables better health outcomes in a member-centric, personalised and
comprehensive holistic solution.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both experts at treating and healing both the physical
and emotional impacts of IBD and have been innovators for whole person
healthcare for a combined 50 years.

 

The Company is initially focusing on chronic costly GI conditions that have
high mental health burden, such as inflammatory bowel disease ("IBD") which
includes the chronic incurable conditions of Crohn's Disease and ulcerative
colitis. Given the common emotional and mental health struggles often
experienced by individuals suffering from a variety of chronic conditions,
Trellus Health considers its approach to have potential utility and demand
across many conditions.

 

The Trellus Elevate™ program incorporates the GRITT™ methodology and
learnings on resilience from clinical research and practice conducted at the
Mount Sinai IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to demonstrate
meaningful improvements in patient outcomes, 71% reduction in Emergency
Department (A&E) visits, and 94% reduction in unplanned hospitalisations,
which the directors of the Company believe indicates the potential for
significant cost savings for healthcare payers and health systems. Patients
with IBD managed with the proprietary resilience methodology also experienced
a 49% reduction in required opioid use and a 73% reduction in corticosteroid
use 12 months following starting the program which is a major indicator of
improved health outcomes(1.)

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information on Trellus Health, visit:
www.trellushealth.com (http://www.trellushealth.com)

 

(1) Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258
(https://www.sciencedirect.com/science/article/pii/S1542356521012258)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFELLFZZLLBBL